help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, D. Y.
Right arrow Articles by Guller, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, D. Y.
Right arrow Articles by Guller, S.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 2 632-637
Copyright © 1998 by The Endocrine Society


Original Studies

Glucocorticoid Effects in the Human Placenta: Evidence That Dexamethasone-Mediated Inhibition of Fibronectin Expression in Cytotrophoblasts Involves a Protein Intermediate1

Diana Y. Yoon, Yuehong Ma, Graciela Krikun, Charles J. Lockwood, Linda LaChapelle and Seth Guller

Departments of Obstetrics and Gynecology (Y.M., G.K., C.J.L., L.L., S.G.) and Biochemistry (S.G.), New York University Medical Center, New York, New York 10016

Address all correspondence and requests for reprints to: Dr. Seth Guller, Department of Obstetrics and Gynecology, New York University Medical Center, Tisch Hospital Room 531, 550 First Avenue, New York, New York 10016.

Oncofetal fibronectin is an extracellular matrix protein that is suggested to play an important role in regulating adherence at uterine-placental interfaces. The purpose of the present study was to elucidate a mechanism through which glucocorticoids (GCs) inhibit the synthesis of FN in human placenta as part of their matrix-suppressive action near parturition. We observed that treatment of cytotrophoblasts isolated from human term placentas for 48 h with 10-7 mol/L dexamethasone (DEX) down-regulated levels of FN expression to 13–19% of control levels in immunoprecipitation, Northern blotting, and enzyme-linked immunosorbent assay experiments. Conversely, GC treatment increased FN expression in placental fibroblasts to 164–310% of control levels in Northern blotting and enzyme-linked immunosorbent assay procedures, suggesting that GC-mediated suppression of FN expression is specific to cytotrophoblasts. Results indicated that the DEX-mediated suppression of FN expression in cytotrophoblasts was not mediated through changes in the stability of FN messenger ribonucleic acid (mRNA). Run-on transcription assays using isolated nuclei suggested that GC treatment did not markedly affect transcription of the FN gene in cytotrophoblasts. To test whether the GC-mediated suppression of FN expression was mediated through a protein intermediate, levels of FN mRNA were examined by Northern blotting in cells treated for 48 h with and without 10-7 mol/L DEX and cycloheximide (CHX; 125 ng/mL). We observed that CHX treatment increased FN expression in DEX-treated cells to 91% of control values. We noted that whereas the presence of 100–300 ng/mL CHX reversed the DEX-mediated inhibition of FN mRNA expression in cytotrophoblasts, it did not alter the overall rates of protein synthesis in DEX-treated and control cells. These data suggest that suppression of FN mRNA expression by GC in cytotrophoblasts requires de novo protein synthesis and is mediated through a short lived intermediate, the synthesis of which is inhibited at low concentrations of CHX. Thus, GC-induced protein intermediates may influence uterine-placental adherence by modulating levels of oncofetal FN at sites of uterine-placental contact.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. P. van Beek, H. Guan, L. Julan, and K. Yang
Glucocorticoids Stimulate the Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in Cultured Human Placental Trophoblast Cells
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5614 - 5621.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
M.-J. Lee, Y. Ma, L. LaChapelle, S. S. Kadner, and S. Guller
Glucocorticoid Enhances Transforming Growth Factor-{beta} Effects on Extracellular Matrix Protein Expression in Human Placental Mesenchymal Cells
Biol Reprod, May 1, 2004; 70(5): 1246 - 1252.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
Y. Ma, C. J. Lockwood, A. L. Bunim, D. A. Giussani, P. W. Nathanielsz, and S. Guller
Cell Type-Specific Regulation of Fetal Fibronectin Expression in Amnion: Conservation of Glucocorticoid Responsiveness in Human and Nonhuman Primates
Biol Reprod, June 1, 2000; 62(6): 1812 - 1817.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
J. S. Ryu, R. J. Majeska, Y. Ma, L. LaChapelle, and S. Guller
Steroid Regulation of Human Placental Integrins: Suppression of {alpha}2 Integrin Expression in Cytotrophoblasts by Glucocorticoids
Endocrinology, September 1, 1999; 140(9): 3904 - 3908.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
L. I. McKay and J. A. Cidlowski
Molecular Control of Immune/Inflammatory Responses: Interactions Between Nuclear Factor-{kappa}B and Steroid Receptor-Signaling Pathways
Endocr. Rev., August 1, 1999; 20(4): 435 - 459.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society